Terms: = Skin cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246
239 results:
1. Muir-Torre Syndrome with Novel Mutation in the msh2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract] [Full Text] [Related]
2. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
Guo Z; Cai Y; Yin W; Huang J
Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
[TBL] [Abstract] [Full Text] [Related]
3. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
4. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of clinicopathologic features, survival, and demographics in sebaceous carcinoma patients with and without Muir-Torre syndrome.
Maloney NJ; Zacher NC; Hirotsu KE; Rajan N; Aasi SZ; Kibbi N
J Am Acad Dermatol; 2023 Aug; 89(2):269-273. PubMed ID: 37003478
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-independent Detection of Inherited Mismatch Repair Deficiency for the Diagnosis of Lynch Syndrome with High Specificity and Sensitivity.
Kansikas M; Vähätalo L; Kantelinen J; Kasela M; Putula J; Døhlen A; Paloviita P; Kärkkäinen E; Lahti N; Arnez P; Kilpinen S; Alcala-Repo B; Pylvänäinen K; Pöyhönen M; Peltomäki P; Järvinen HJ; Seppälä TT; Renkonen-Sinisalo L; Lepistö A; Mecklin JP; Nyström M
Cancer Res Commun; 2023 Mar; 3(3):361-370. PubMed ID: 36875157
[TBL] [Abstract] [Full Text] [Related]
7. Clinical factors associated with skin neoplasms in individuals with Lynch syndrome in a longitudinal observational cohort.
Zhong CS; Horiguchi M; Uno H; Ukaegbu C; Chittenden A; LeBoeuf NR; Syngal S; Nambudiri VE; Yurgelun MB
J Am Acad Dermatol; 2023 Jun; 88(6):1282-1290. PubMed ID: 36773823
[TBL] [Abstract] [Full Text] [Related]
8. Deficient mismatch repair is detected in large-to-giant congenital melanocytic naevi: providing new insight into aetiology and diagnosis.
Wei B; Gu J; Gao B; Bao Y; Duan R; Li Q; Xie F
Br J Dermatol; 2023 Jan; 188(1):64-74. PubMed ID: 36689509
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review.
Aziz S; O'Sullivan H; Heelan K; Alam A; McVeigh TP
Fam Cancer; 2023 Apr; 22(2):167-175. PubMed ID: 36418753
[TBL] [Abstract] [Full Text] [Related]
10. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract] [Full Text] [Related]
11. Lynch syndrome: An unusal case of familial cancer unearthed.
Dhar S; Mannan AU; Singh JJ; Dhar S; Pradhan S
Indian J Pathol Microbiol; 2022; 65(2):465-467. PubMed ID: 35435397
[TBL] [Abstract] [Full Text] [Related]
12. Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors.
Gambichler T; Finis C; Abu Rached N; Scheel CH; Becker JC; Lang K; Käfferlein HU; Brüning T; Abolmaali N; Susok L
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1241-1247. PubMed ID: 35419731
[TBL] [Abstract] [Full Text] [Related]
13. Sebaceous Carcinoma Arising in Ovarian Teratoma: First Report Associated With Germline Mismatch Repair Gene Mutation.
Murray J; McIlwaine P; Morrison PJ; McCluggage WG
Int J Gynecol Pathol; 2022 Nov; 41(6):608-614. PubMed ID: 35077082
[TBL] [Abstract] [Full Text] [Related]
14. Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome).
Miao Y; Kolb F; Tomasic G; Lupu J; Routier E; Robert C
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():74-76. PubMed ID: 34855250
[TBL] [Abstract] [Full Text] [Related]
15. Eruptive nevi in a patient with constitutional mismatch repair deficiency (CMMRD).
Vassantachart JM; Zacher NC; Teng JMC
Pediatr Dermatol; 2022 Jan; 39(1):91-93. PubMed ID: 34787334
[TBL] [Abstract] [Full Text] [Related]
16. Muir-Torre syndrome: a case of unusual coexisting genetic mutations.
Cino D; Drumm C; Sheahan K; D'Arcy C; Nolan N; Hoti E; Winter D; O'Duffy F; Dolan R; Moriarty B
Clin Exp Dermatol; 2022 Mar; 47(3):602-604. PubMed ID: 34762321
[TBL] [Abstract] [Full Text] [Related]
17. Mismatch Repair Protein Expression and Microsatellite Instability in Cutaneous Squamous Cell Carcinoma.
Gambichler T; Ganjuur N; Tannapfel A; Vogt M; Scholl L; Abu Rached N; Bruckmüller S; Skrygan M; Becker JC; Käfferlein HU; Brüning T; Lang K
Curr Oncol; 2021 Aug; 28(5):3316-3322. PubMed ID: 34590599
[TBL] [Abstract] [Full Text] [Related]
18. Clinical and Molecular Features of skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract] [Full Text] [Related]
19. Molecular Genetics of Sebaceous Neoplasia.
North JP
Surg Pathol Clin; 2021 Jun; 14(2):273-284. PubMed ID: 34023105
[TBL] [Abstract] [Full Text] [Related]
20. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract] [Full Text] [Related]
[Next]
